C12N 15/8636
Vaccina virus vectors
Official title: {Vaccina virus vectors}
C12N15/8636 (Vaccina virus vectors) appears on 26 US grants and 32 published applications in this corpus.
Search patents in C12N- Granted patents
- 26
- Published applications
- 32
- Assignees
- 31
- Inventors
- 37
- Latest grant
- 17 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 1 |
| 2010 | 1 | 2 |
| 2011 | 0 | 2 |
| 2012 | 1 | 3 |
| 2013 | 1 | 2 |
| 2014 | 0 | 1 |
| 2015 | 5 | 0 |
| 2016 | 3 | 4 |
| 2017 | 1 | 4 |
| 2018 | 4 | 2 |
| 2019 | 1 | 2 |
| 2020 | 2 | 3 |
| 2021 | 2 | 0 |
| 2022 | 1 | 3 |
| 2023 | 1 | 0 |
| 2024 | 2 | 0 |
| 2025 | 0 | 0 |
| 2026 | 1 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Vaccines and uses thereof to induce an immune response to SARS-CoV217 Mar 2026US 12,577,589 B2GeoVax, Inc.
- Chimpanzee adenoviral vector-based filovirus vaccines27 Feb 2024US 11,913,013 B2Sabin Vaccine Institute
- Multivalent HIV vaccine boost compositions and methods of use13 Feb 2024US 11,897,919 B2GeoVax, Inc.
- Oncolytic virus for expression of immune checkpoint modulators10 Oct 2023US 11,779,619 B2Transgene S. A.
- Stable recombinant MVA vectors comprising modified RSV genes with reduced intramolecular recombinatorial activity18 Jan 2022US 11,225,673 B2Bavarian Nordic A/S
- Nucleic Acids Encoding TGF-Beta Inhibitor and IL-12 and Uses Thereof13 Aug 2026US 2026/0234667 A1KaliVir Immunotherapeutics, Inc.
- Vaccines and uses thereof to induce an immune response to sars-cov215 Dec 2022US 2022/0396810 A1GeoVax, Inc.
- Multivalent hiv vaccine boost compositions and methods of use14 Apr 2022US 2022/0112248 A1GeoVax, Inc.
- Chimpanzee adenoviral vector-based filovirus vaccines3 Mar 2022US 2022/0064669 A1Sabin Vaccine Institute
- Oncolytic virus for expression of immune checkpoint modulators25 Jun 2020US 2020/0197457 A1Transgene S. A.
Most cited
By later US patents
- Intrathecal and intratumoral superantigens to treat malignant disease18US 7,776,822 B2Jenquest · 2010
- Recombinant modified vaccinia ankara (MVA) vaccinia virus containing restructured insertion sites18US 9,133,480 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2015
- Modified vaccinia Ankara (MVA) virus recombinants comprising heterologous coding sequences inserted into the intergenic regions between essential genes15US 9,133,478 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2015
- Poxvirus expression system15US 9,273,327 B2Isis Innovation Limited · 2016
- Oncolytic virus for expression of immune checkpoint modulators9US 10,555,981 B2Transgene S.A. · 2020